Cat. No. 3716
Alternative Name: NSC 680410
Chemical Name: 4-[[(2,5-Dihydroxyphenyl)methyl]ami
Biological Activityp210bcr/abl tyrosine kinase inhibitor (IC50 = 14 μM). Induces apoptosis in T-lymphoblastic human leukemia cell lines (IC50 values range from 16.8 to 216.3 nM) in vitro. Displays selectivity for chronic myelogenous leukemia (CML) myeloid progenitors in vitro.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Avramis et al (2002) In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Cancer Chemother.Pharmacol. 50 479. PMID: 12451475.
Mow et al (2002) Effects of bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99 664. PMID: 11781252.
Svingen et al (2000) Effects of the bcl/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin.Cancer Res. 6 237. PMID: 10656455.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Adaphostin include:
Xia et al (2014) EZH2 silencing with RNA interference induces G2/M arrest in human lung cancer cells in vitro. Biomed Res Int 2014 348728. PMID: 24745014.
Do you know of a great paper that uses Adaphostin from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Adaphostin, supplier, p210bcr/abl, kinases, inhibitors, inhibits, chronic, myelogenous, leukaemia, leukemia, CML, NSC680410, Tocris Bioscience, Abl Kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitorLTURM 34
Potent DNA-PK inhibitorMLi-2
Potent and selective LRRK2 inhibitorLTURM 36
PI 3-kinase δ inhibitorPI 3065
Potent and selective PI 3-kinase p110δ inhibitorAZ PFKFB3 67
Potent and selective PFKFB3 inhibitorSTOCK2S 26016
Lysine deficient protein kinase (WNK) signaling inhibitorrac-CCT 250863
Potent Nek2 inhibitorRoscovitine
Potent, selective cyclin-dependent kinase inhibitorEnzastaurin
Potent PKCβ inhibitorBMS 265246
Potent cdk1/2 inhibitorAutocamtide-2-related inhibitory peptide, myristoylated
CaM kinase II inhibitor; enhanced cell permeable derivative of Autocamtide-2-related inhibitory peptideMP A08
Selective ATP competitive SphK1 and 2 inhibitor; cell permeable
March 18 - 22, 2017
Little Rock, ARK, USA